Results 91 to 100 of about 20,250 (180)

Synergistic effects of the combination of trametinib and alpelisib in anaplastic thyroid cancer with BRAF and PI3KCA co-mutations

Heliyon
Background: Anaplastic thyroid cancer (ATC), a rare and aggressive malignancy with a poor prognosis, has shown promise with the approved dabrafenib/trametinib combination for BRAFV600E mutation.
Chiao-Ping Chen, Shu-Fu Lin, Chun-Nan Yeh, Wen-Kuan Huang, Yi-Ru Pan, Yu-Tien Hsiao, Chih-Hong Lo, Chiao-En Wu   +7 more
doaj   +1 more source

Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom

British Journal of Haematology, Volume 209, Issue 2, Page 747-754, August 2026.
Trametinib (MEK inhibitor) shows efficacy in refractory and high‐risk adult histiocytic neoplasms. At a median follow‐up of 21.4 months, the clinical response rate was 81% (30/37) and the radiological response was 68% (25/37) (n = 37).
Rodothea Amerikanou, Talha Munir, Kristian Bowles, Christopher McNamara, Nikesh Chavda, Elizabeth Price, Jagdish Adiyodi, Alasdair Coles, Philippa Kelsey, Jeffery Smith, Richard Adams, Hayder Hussein, Rui Zhao, Trung Nguyen, Matthew Collin, Satyen Gohil   +15 more
wiley   +1 more source

Combinational Inhibition of MEK and AKT Synergistically Induces Melanoma Stem Cell Apoptosis and Blocks NRAS Tumor Growth

Cells
Malignant melanoma is a lethal skin cancer containing melanoma-initiating cells (MICs), implicated in tumorigenesis, invasion, and drug resistance, and characterized by an elevated expression of stem cell markers, including CD133.
Ryyan Alobaidi, Nusrat Islam, Toni Olkey, Yogameenakshi Haribabu, Mathew Shamo, Peter Sykora, Cynthia M. Simbulan-Rosenthal, Dean S. Rosenthal   +7 more
doaj   +1 more source

Application of Systems Genetics to Investigate Molecular Pathology of Early‐Onset Colorectal Cancer

Chemical Biology &Drug Design, Volume 108, Issue 2, August 2026.
Early‐onset colorectal cancer (EOCRC) presents a complex molecular landscape that requires integrated multi‐omics approaches. This article reviews current applications of systems genetics in EOCRC research and provides a step‐by‐step protocol for network‐based analyses featuring PIK3CA to demonstrate practical application for researchers of all levels.
Minjae J. Kim, Sydney L. Carr, Vishnutheertha Kulkarni, Mary‐Louise Manchadi   +3 more
wiley   +1 more source

RAS Inhibitor RMC‐7977 Blocks Vascular Overgrowth of NRASQ61R Mutant Endothelial Cells

Journal of Cellular and Molecular Medicine, Volume 30, Issue 15, August 2026.
ABSTRACT RAS mutations occur in patients with several types of vascular anomalies, but effective treatments remain limited. To address this need, we evaluated the RAS (ON) multi‐selective inhibitor RMC‐7977 in human endothelial cells (ECs) expressing the NRASQ61R mutation found in kaposiform lymphangiomatosis (KLA).
Sara Alharbi, Svatava Merkle, Patricia Pastura, C. Griffin McDaniel, George S. Zaky, Andrew M. Waters, Timothy D. Le Cras   +6 more
wiley   +1 more source

Selumetinib as a Target Therapy in Progressive Paediatric Low‐Grade Gliomas—Case Series (pLGG)

Journal of Paediatrics and Child Health, Volume 62, Issue 8, Page 1499-1508, August 2026.
ABSTRACT Background Optic pathway gliomas (OPGs) occur in 15%–20% of children with neurofibromatosis type 1 (NF1). While smaller gliomas may be only monitored, the current standard of care for symptomatic ones relies on chemotherapy, most commonly carboplatin and vincristine.
Laura Trapani, Giulia Gortani, Andrea Magnolato, Flora Maria Murru, Elisabetta Cattaruzzi, Laura Diplotti, Paola Michieletto, Silvia Giganti, Davide Zanon, Alessandra Maestro, Valentina Kiren, Egidio Barbi, Irene Bruno   +12 more
wiley   +1 more source

Trametinib Therapy for Hypertrophic Cardiomyopathy and Pulmonary Hypertension in a Child With RAF1-Related Noonan Syndrome (p.Ser257Leu): A Case Report. [PDF]

Clin Case Rep
Nilsson CN, Aljohani OA, Smith MA, Durand R, Sheyanth IN, Nawaytou H, Stieglitz E, Valle R, Datar SA.   +8 more
europepmc   +1 more source

Reduced-Dose Dabrafenib-Trametinib for BRAF V600E-Mutant Lung Adenocarcinoma in a Very Elderly Patient With ECOG PS 2. [PDF]

Respirol Case Rep
Suyama S, Sunata K, Uchibori K, Shinomiya S, Tani T, Takahashi S.   +5 more
europepmc   +1 more source

Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer. [PDF]

Cell Rep Med
Zeng PYF, Meens J, Karimi AH, Pan H, Cecchini MJ, Jarycki L, Ryan SB, Dawson AE, Shaikh MH, Palma DA, Winquist E, Gunaratnam L, Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC.   +16 more
europepmc   +1 more source

Anaplastic Thyroid Carcinoma With Cardiac Dysfunction Developed During Combination Therapy With Dabrafenib and Trametinib. [PDF]

Cureus
Maezumi S, Tanaka H, Ueda Y, Kondo T, Tsukahara K.   +4 more
europepmc   +1 more source